The Efficacy of Allergen Immunotherapy with Cat Dander in Reducing Symptoms in Clinical Practice
Table 1
Patient characteristics.
Cat immunotherapy
Other immunotherapy
value
Gender, (%)
Male
14 (40%)
17 (49%)
Female
21 (60%)
18 (51%)
0.47
Age (years)
Mean (SD)
49.3 (14.7)
55 (13.6)
0.11
Range
29–86
28–89
Baseline FEV1 (%)
Mean (SD)
84.4 (21.8)
86.6 (17.9)
0.66
Range
38–117
43–127
History of allergic rhinitis
34 (97%)
35 (100%)
0.31
Mean duration immunotherapy (years) (SD)
5.2 (1.9)
5.5 (2.5)
0.36
Inhaled corticosteroids , (%)
26 (74%)
23 (66%)
0.43
Treatment antigens , (%)
Dog
10 (29%)
9 (26%)
0.79
Pollen
16 (46%)
25 (71%)
0.02
Mold
3 (9%)
15 (43%)
0.001
Dust/mite
20 (57%)
33 (94%)
0.001
Allergic asthmatic patients on cat immunotherapy or traditional immunotherapy. Comparisons between groups were made using the test and test where appropriate.
